News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

inGenium Research, Inc. Following Year Of Rapid Growth, Changes Name To Ockham Development Group, Inc.


10/19/2005 5:12:48 PM

CARY, N.C., Feb. 22 /PRNewswire/ -- inGenium Research, Inc., a privately held Contract Research Organization headquartered in Cary, has changed its name to Ockham Development Group, Inc. The new drug development partnering company consists of three separate business units.

Ockham Development provides clinical development services. Ockham EDGE(TM) provides strategic planning and oversight. Ockham Ventures(TM) is the company's business venture group focusing on drug development partnering.

President and Chief Executive Officer Joshua S. Baker, Ph.D., an industry executive with more than 20 years of pharmaceutical management and drug development experience who has more than doubled the size of the company over the past year, said the new identity represents the company's commitment to a new approach to drug development.

"As we continue to grow, it becomes increasingly important that we focus and enhance our relationship with our customers and partners," said Dr. Baker. "The Ockham's Razor principal teaches us that processes need not be overly complicated. Creating new drug development partnerships through clear, simple approaches helps to ensure our long-term growth and stability as a company."

Ockham Development, which has opened offices in Philadelphia and in Tacoma, Wash., in the past year, has grown from less than 20 employees a year ago to nearly 50 today. The workforce is expected to increase this year to more than 100.

Ockham provides integration of business, planning, and development services to drug companies. The company functions through traditional fee for service as well as leveraged-based partnerships, strategic planning, licensing services, and equity-based investments to the pharmaceutical and biotechnology industry.

Ockham's product and service capabilities are diverse and innovative. These services are intended to provide small to mid-size biotechnology companies, venture capital funds, and universities with fully integrated capabilities and functionality for cost-effective, highly aggressive, collaborative risk-sharing, and simple drug development options to achieve the maximum return on investment.

Ockham Development Group, Inc. is a privately held drug development organization, headquartered in Cary, North Carolina, and with offices in Philadelphia and in Tacoma, Washington. Focused on providing clinical research, strategic development services and financial strategies to pharmaceutical and biotechnology companies, Ockham Development Group provides assistance to companies in the areas of strategic planning, technology transfer, licensing, regulatory planning and submissions, pre-clinical development, and manufacturing, as well as providing fully integrated clinical trials support of clinical operations, data management and biostatistics, and regulatory dossier compilations.

For information contact: Josh Baker, President and CEO Dan Headrick Ockham Development Group Public Relations 919.462.8867 919.332.9303 jsbaker@ockham.comheadrickdan@hotmail.com

Ockham Development Group, Inc.

CONTACT: Josh Baker, President and CEO of Ockham Development Group,+1-919-462-8867, or jsbaker@ockham.com ; or Public Relations, Dan Headrick forOckham Development Group, +1-919-332-9303, or headrickdan@hotmail.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES